# Shattuck Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shattuck-labs

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.shattucklabs.com
- Total disclosed funding: $83M
- Latest round: Series B (Jun 12, 2020)
- Investors on record: 9

## About

Shattuck Labs, Inc. is a biotechnology company focused on creating innovative biologic therapeutics, primarily targeting inflammatory autoimmune disorders through its lead product, SL-325, a monoclonal antibody antagonist.Founded in 2016 in Austin, US, Shattuck Labs, Inc. develops biologic therapeutics, including its lead product SL-325 targeting Death Receptor 3 (DR3) for chronic inflammatory conditions. The company has successfully raised a total of USD 201.99 mn through several funding rounds, the latest being an IPO on December 21, 2023, which raised USD 201.99 mn. Josiah Hornblower is the CEO and co-founder of the company, which has completed a total of 5 deals to date.Shattuck Labs specializes in the development of innovative biologic therapeutics, with a primary focus on its lead product, SL-325. This monoclonal antibody antagonist targets Death Receptor 3 (DR3), involved in the TL1A/DR3 signaling pathway, relevant in treating Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune disorders. The company employs proprietary protein engineering techniques to enhance SL-325's efficacy by ensuring a deeper blockade of the DR3 receptor. Shattuck Labs serves healthcare providers and pharmaceutical partners in North America and Europe, where there is a growing demand for advanced therapies addressing unmet needs in the autoimmune disease sector.In the most recent fiscal year of 2024, Shattuck Labs reported revenue of USD 5.72 mn and an EBITDA of -USD 74.59 mn. The company's revenue generation is supported by partnerships and collaborations with pharmaceutical companies and research institutions, utilizing licensing agreements for its proprietary technologies and product candidates, including SL-325.Shattuck Labs is focused on expanding its product offerings and entering new markets. Following a recent private placement that raised USD 30 mn on December 21, 2023, the company plans to utilize these funds to advance the development and commercialization of SL-325 and other pipeline products. Targeted markets for expansion include further penetration into European regions and potential entry into Asia, with strategic plans set for implementation by 2025.

## Funding rounds

- Series B, Jun 12, 2020, $83M — Hatteras Venture Partners, Piper Sandler, Fidelity Investments, Redmile Group, EcoR1 Capital, Partner Fund Management, Emerson Collective, Janus Henderson Investors, Avidity Partners

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Partner Fund Management — Series B
- Emerson Collective — Series B
- Janus Henderson Investors — Series B
- Avidity Partners — Series B